Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 366 clinical trials
Featured trial
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell carcinoma (RCC) is an incurable condition. Current therapy for this disease consists of the serial administration

clear cell carcinoma
metastatic cancer
carcinoma
clear cell renal cell carcinoma
primary cancer
  • 210 views
  • 22 Dec, 2020
  • 1 location
Featured trial
AREN03B2: Study of Kidney Tumors in Young Patients

AREN03B2: Study of Kidney Tumors in Young Patients

  • 36 views
  • 08 Nov, 2020
  • 1 location
Featured trial
AREN03B2: Renal Tumors Classification, Biology, and Banking Study

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

  • 106 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with REGN2810 will be determined, followed by an expansion stage. During …

renal function tests
programmed cell death 1 ligand 1
renal cell cancer
cancer
measurable disease
  • 2 views
  • 23 Nov, 2020
  • 3 locations
Featured trial
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor …

systemic therapy
carcinoma
nivolumab
VEGFR2
tyrosine
  • 57 views
  • 15 Sep, 2020
  • 1 location
Featured trial
Procurement of Human Biospecimens for Research

Procurement of Human Biospecimens for Research

  • 53 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Procurement of Human Biospecimens for Research

Procurement of Human Biospecimens for Research

  • 80 views
  • 23 Nov, 2020
  • 1 location
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

This is first in human study of DFF332, a small molecule that targets a protein called HIF2α. By acting on HIF2α, DFF332 may be able to stop the growth of certain types of cancer. DFF332 will be tested at different doses as single agent and in combination with Everolimus (RAD001, …

carcinoma
clear cell renal cell carcinoma
mtor inhibitor
vegf
rad001
  • 16 views
  • 30 Jun, 2022
  • 10 locations
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

  • 0 views
  • 20 Jun, 2022
  • 1 location
  • 0 views
  • 25 Jan, 2021
  • 26 locations